The company has closed series B financing under the round led by Canaan and DFJ, and participants included GE Ventures, Section 32, Casdin Capital, LifeForce Capital and other undisclosed investors.

Vineti will use an additional capital to further progress its first cloud-based “platform of record”, which is specifically designed to move new personalized therapies such as CAR-T cell therapy into mainstream medicine.

The funding will also help Vineti to further expand its operations in Europe and Asia-Pacific.

The configurable and cloud-based software platform is said to enhance cell and gene therapy product performance, promote regulatory compliance and enable wider access for patients.

Vineti ‘s platform automates, directs and simplifies the complex workflows behind personalized therapies, as well as supports pharmaceutical partners address emerging opportunities and challenges as these therapies move into mainstream medicine.

The platform also allows seamless integrations with other parts of the therapy ecosystem.

Vineti CEO and co-founder Amy DuRoss said: "We are in a crucial window to get production and delivery of personalized therapies right for a rapidly growing number of patients who are desperately in need.

“Vineti is humbled to be working with the leading scientific, clinical trial, and commercial teams in personalized medicine.

“We are leveraging the best of SIlicon Valley “critical path” enterprise software to ensure that the right therapy gets to the right patient at the right time, safely and cost-effectively.”

Canaan general partner Nina Kjellson, and Section 32 managing partner and Foundation Medicine chairman Dr Michael Pellini will join as board of directors in Vineti.

In 2017, Novartis and Gilead firm Kite’s first two CAR-T cell therapies secured approval from the US Food and Drug Administration (FDA).

Under commercial agreement, Vineti provided its critical cloud-based infrastructure to Kite for commercially accessing its Yescart therapy.